The addition of gemcitabine to pazopanib significantly increased the progression-free survival rate (PFSR) in patients with soft tissue sarcoma at 12 weeks compared to pazopanib alone, according to results of a phase 2 clinical trial.
Although the results suggested the combination seems to have clinical activity, the researchers advised phase 3 trials are needed to confirm.
In this multicenter, randomized phase 2…
Take a look at some of our conference coverage, visit our roundup section.
A durable response was found in patients with synovial sarcoma treated with ADP-A2M4 (Adaptimmune Therapeutics), according to data presented at the virtual Connective Tissue Oncology Society (CTOS) annual meeting.
Updated data from the phase 1 trial…
The addition of gemcitabine to pazopanib significantly increased the progression-free survival rate (PFSR) in patients with soft tissue sarcoma at 12 weeks compared to pazopanib alone, according to results of a phase 2 clinical trial.
…A new study has found that a commonly prescribed anti-depressant may halt growth of a type of cancer known as childhood sarcoma, at least in mice and laboratory cell experiments. The findings, from researchers at Karolinska Institutet in Sweden and MD Anderson Cancer Centre in Texas, ignite hope…